Potential cost effectiveness of a rotavirus vaccine in Chile Evaluación de costo-efectividad de la vacuna anti-rotavirus en Chile
Author
dc.contributor.author
Constenla, Dagna
Author
dc.contributor.author
O'Ryan Gallardo, Miguel
Author
dc.contributor.author
Navarrete, María S.
Author
dc.contributor.author
Antil, Lynn
Author
dc.contributor.author
Rheingans, Richard D.
Admission date
dc.date.accessioned
2019-03-11T12:51:17Z
Available date
dc.date.available
2019-03-11T12:51:17Z
Publication date
dc.date.issued
2006
Cita de ítem
dc.identifier.citation
Revista Medica de Chile, Volumen 134, Issue 6, 2018, Pages 679-688
Identifier
dc.identifier.issn
00349887
Identifier
dc.identifier.issn
07176163
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/164181
Abstract
dc.description.abstract
Background: Cost effectiveness studies are essential to assess the real value of interventions with preventive or therapeutic objectives. Aim: To assess the theoretical cost-effectiveness of a vaccine against rotavirus in Chilean children of less than five years of age. Material and methods: An economic model was developed based on information on disease incidence, health care costs associated with treatment and the effectiveness and costs of vaccination. Net disease and vaccination costs were estimated from the health system perspective and were compared with life years and disability-adjusted life-years (DALYs) gained using a 3% discount rate. Local administrative and accounting hospital data and vaccine efficacy data were used to estimate healthcare costs and cost-effectiveness of vaccination. Results: A rotavirus vaccination program would prevent 10 deaths due to rotavirus gastroenteritis, 6,245 related hospitalizations and 41,962 outpatient visits during the first five years of li